CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ArcherDX, Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ArcherDX, Inc
2477 55th Street, Suite 202
BOULDER, CO  80301  United States Fax: (303) 736-7150f:303 736-7150
This company was Merged or Acquired on 10/2/2020.
On 12/15/2020, the Company filed a Registration Withdrawal Request of its Form S-1 (File No. 333-238993) with the SEC, initially filed with the Commission on June 5, 2020. The Company is seeking withdrawal of the Registration Statement because the registrant has determined not to pursue the public offering.
This is a Subsidiary, click here for the Parent Company
Business Summary
ArcherDX, Inc. is a genomics company. The Company’s product development platform, with its anchored multiplex polymerase chain reaction (AMP), enables to develop products and services that allow for therapy optimization and cancer monitoring. The Company offers research use only (RUO) products, in-vitro diagnostic (IVD) products and services for clinical applications. Its RUO product lines consist of deoxyribonucleic acid (DNA)-based VariantPlex, ribonucleic acid (RNA)-based FusionPlex, circulating tumor DNA (ctDNA)-based LiquidPlex and RNA-based Immunoverse, and personalized cancer monitoring (PCM). The Company's offerings include commercial RUO products and services that laboratories use to conduct genomic analysis for therapy optimization and cancer monitoring. The Company’s modular product development platform combines its AMP chemistry, target-specific primers, ancillary reagents, and bioinformatics software to detect mutations.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202012/31/2019YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
8071 Medical laboratories
2835 In vitro and in vivo diagnostic substances

Business Names
Business Name
ARCHER DX
RCHR

General Information
Number of Employees: 335 (As of 3/31/2020)
Outstanding Shares: 9,246,778 (As of 6/5/2020)
Stock Exchange: NASD
Federal Tax Id: 383944751
Fax Number: (303) 736-7150


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 25, 2023